Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB002.1T in Advanced Solid Tumors
NCT03636750Phase 1Completed
- Sponsor
- Huabo Biopharm
- Start
- Jun 2018
- Primary completion
- Feb 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of HB002.1T in solid tumor (6 arms), sponsored by Huabo Biopharm. Primary endpoint: Dose-limiting toxicity. Started Jun 2018; status: completed.
02
Drugs
HB002.1T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03636750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636750.